title: Tosufloxacin deposits in compromised corneas.
abstract: OBJECTIVE
  To report the adverse effects of topical tosufloxacin in two patients with corneal deposits in compromised cornea.
  
  
  METHODS
  Tosufloxacin was administered topically to a 13-month-old girl after penetrating keratoplasty in the left eye. Three days posttransplantation, corneal precipitations appeared and thereafter continuously increased. An 80-year-old woman, who maintained postoperative multiple topical medications including tosufloxacin, presented dense white deposits in the left eye a month postoperation. In both cases, the deposits showed a granular pattern and were limited to areas of large epithelial defects. After discontinuation of tosufloxacin, the deposits slowly decreased and completely disappeared in a few weeks. In the former case, corneal re-epithelialization was significantly disturbed and resulted in anterior stromal opacity, whereas visual acuity and visualization of the retina were severely interfered in the latter case.
  
  
  CONCLUSIONS
  Tosufloxacin can precipitate especially on compromised corneal surfaces. Therefore, topical tosufloxacin should be avoided in patients who are at risk of losing corneal surface integrity.
authors.affiliation: *MD †MD, PhD Department of Ophthalmology, Seoul National University Hospital, Seoul, Republic of Korea (all authors); Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea (MKK, WRW, and HJC); and Department of Ophthalmology, Seoul National University Hospital, Healthcare System Gangnam Center, Seoul, Republic of Korea (HJC).
authors.forename: Yong Dae
authors.initials: YD
authors.lastname: Kim
authors.forename: Mee Kum
authors.initials: MK
authors.lastname: Kim
authors.forename: Won Ryang
authors.initials: WR
authors.lastname: Wee
authors.forename: Hyuk Jin
authors.initials: HJ
authors.lastname: Choi
mesh_terms: D000287:Administration, Topical; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003316:Corneal Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects*; D015745:Granuloma, Foreign-Body / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D006801:Humans; D007223:Infant; D015948:Keratoplasty, Penetrating; D009287:Naphthyridines / Q000008:administration & dosage / Q000009:adverse effects*; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; C055185:tosufloxacin